Listed for reference — companies are not ranked in any particular order.
| Market Size 2024 | US$ 21,460.8 Million |
| Market Size 2031 | US$ 50,427.8 Million |
| CAGR 2025–2031 | 13.0% |
| Segments | By Therapy Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Immune Checkpoint Inhibitors, Cancer Vaccines, Gene Therapy, Other Therapy Types) | By Indication (Blood Cancer, Lung Cancer, Breast Cancer, Colorectum Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Duct Cancer, Thyroid Cancer, Other Indications) | By End User (Hospital Pharmacies, Retail Pharmacies, Online Stores) | By End User (Hospital Pharmacies, Retail Pharmacies, Online Stores) |
| Geographies | Western Europe(Belgium, the Netherlands, Luxembourg, Germany, France, Italy, Spain, Switzerland, Sweden, Austria, the United Kingdom, Denmark, Portugal, Norway, Finland) |
| Deliverables | Historical analysis with CAGR · PEST & SWOT analysis · Market Size at Global, Regional, and Country Levels · Competitive heat map · Company profiles · Excel dataset |
| Report Code | BMIPUB00033510 |
| Lead Analyst | Krishna Sunthwal — Analyst, Research · View Profile |
Gain actionable insights with 187 pages of in-depth Western Europe Cancer Targeted Therapy Market, including historical trends, 7-year market forecasts, SWOT analysis, competitive landscapes, and downloadable Excel datasets in a single comprehensive package.